I-Lenvatinib Mesylate Intermediate CAS 15568-85-1 Purity >97.0% (HPLC) Factory

Incazelo emfushane:

5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione

I-CAS: 15568-85-1

Ubumsulwa: >97.0% (HPLC)

Ukubukeka: Impushana Ephuzi

I-Intermediate ye-Lenvatinib Mesylate CAS 857890-39-2

Thintana: UDkt. Alvin Huang

Iselula/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Imininingwane Yomkhiqizo

Imikhiqizo Ehlobene

Omaka bomkhiqizo

Incazelo:

Chemical Properties:

Igama Lekhemikhali 5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione
Omqondofana 5-(Methoxymethylene) I-Meldrum's Acid;Ukungcola kwe-Cabozantinib 56;I-Lenvatinib Ukungcola 79
Inombolo ye-CAS 15568-85-1
Inombolo yeCAT I-RF-PI1967
Isimo Sesitoko Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani
I-Molecular Formula I-C8H10O5
Isisindo samangqamuzana 186.16
I-Melting Point 132.0~134.0℃
Ukuminyana 1.297±0.06 g/cm3
Ibhrendi I-Ruifu Chemical

Imininingwane:

Into Imininingwane
Ukubukeka Impushana Ephuzi
1 H NMR Spectrum Ihambisana Nesakhiwo
Ukuhlanzeka / Indlela Yokuhlaziya
>97.0% (HPLC)
Ukungcola Okuphelele <3.00%
Izinga Lokuhlola I-Enterprise Standard
Ukusetshenziswa I-Intermediate ye-Lenvatinib Mesylate (CAS: 857890-39-2)

Iphakheji nesitoreji:

Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende

Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama

Izinzuzo:

1

I-FAQ:

Isicelo:

I-5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione (CAS:15568-85-1) iphakathi kwe-Lenvatinib Mesylate (CAS: 857890-39-2).I-Lenvatinib iyisidakamizwa somdlavuza we-thyroid esakhiwe yi-Eisai Corporation yaseJapane (Ikhodi: E7080), eyingxenye ye-inhibitor ye-oral multi-receptor tyrosine kinase (RTK) futhi ingavimbela umsebenzi we-kinase we-vascular endothelial growth factor (VEGF) Receptors VEGFR1 ( I-FLT1), i-VEGFR2 (KDR), ne-VEGFR3 (FLT4).I-Lenvatinib ingaphinde ivimbele ukubandakanyeka kwamanye ama-RTK ku-angiogenesis ye-pathological, ukukhula kwesimila, nokuqhubeka komdlavuza ngaphandle kwemisebenzi yawo evamile yamaselula kuhlanganise ne-fibroblast growth factor (FGF) receptors FGFR1, 2, 3, kanye ne-4;i-platelet-derived growth factor receptor (PDGFR [alpha]), i-KIT, ne-RET.[Izinkomba]: I-Lenvatinib ifanelekela ukwelapha iziguli ezinomdlavuza wegilo wokuphindaphinda kwendawo noma uhlobo lwe-metastasis, uhlobo lwe-progressivity kanye nohlobo oluhlukanisiwe lwe-radioactive iodine-refractory.NgoFebhuwari 13, 2015, i-US FDA yagunyaza isidakamizwa esilwa nomdlavuza i-Lenvatinib sokwelapha umdlavuza wegilo.I-Lenvatinib iyi-multi-target enzyme inhibitor, ekwazi ukuvimbela i-VEGFR2 ne-VEGFR3 (i-vascular endothelial growth factor receptor).Igama lokuhweba le-Lenvatinib yi-Lenvima.Ngomhla zingama-20 kuNhlaba wezi-2015, i-European Medicines Agency (EMA) igunyaze i-Lenvatinib yokwelashwa komdlavuza wegilo wegilo (DTC) ohlaselayo, othuthuke kakhulu noma ometastatic (papillary, follicular, Hurthle type) thyroid cancer (DTC).Ocwaningweni, isikhathi esimaphakathi sokusinda kweziguli ezine-radioactive iodine-refractory DTC ezilashwe nge-Lenvatinib kwakuyizinyanga eziyi-18 kanti inani leziguli ezithatha i-placebo yizinyanga ezi-3 kuphela.

Bhala umyalezo wakho lapha futhi usithumelele wona